Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jinyu Bio-Technology CoSHSE:600201 -1.82%65 PB Ratio is 2.30 as of Jul. 22, 2026, which is 34% below its 10-year median of 3.51. GuruFocus rates SHSE:600201 with a GF Score™ of 65/100 and a GF Value™ of ¥8.34 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,229 Biotechnology companies, Jinyu Bio-Technology Co ranks better than 58.34% on this metric.
The historical rank and industry rank for Jinyu Bio-Technology Co's PB Ratio or its related term are showing as below:
SHSE:600201'
s PB Ratio Range Over the Past 10 Years
Min: 1.2 Med: 3.51 Max: 8.35
Current: 2.3
During the past 13 years, Jinyu Bio-Technology Co's highest PB Ratio was 8.35. The lowest was 1.20. And the median was 3.51.
SHSE:600201's PB Ratio is ranked better than 58.34% of 1229
companies
in the Biotechnology industry
Industry Median: 2.82
vs SHSE:600201: 2.30
During the past 12 months, Jinyu Bio-Technology Co's average Book Value Per Share Growth Rate was 3.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 1.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 6.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Jinyu Bio-Technology Co was 61.40% per year. The lowest was 0.40% per year. And the median was 12.40% per year.
Back to Basics: PB Ratio
Jinyu Bio-Technology Co (SHSE:600201) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600201 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Jinyu Bio-Technology Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinyu Bio-Technology Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jinyu Bio-Technology Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Jinyu Bio-Technology Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Jinyu Bio-Technology Co (SHSE:600201) has a PB Ratio of 2.30 as of Jul. 22, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jinyu Bio-Technology Co and its competitors. This is 34% below median its historical median of 3.51. Over the past decade, Jinyu Bio-Technology Co's PB Ratio has ranged from 1.20 to 8.35. According to the industry distribution chart, Jinyu Bio-Technology Co ranks #512 out of 1229 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Jinyu Bio-Technology Co's PB Ratio too high?
Jinyu Bio-Technology Co's current PB Ratio of 2.30 is 34% below median its 10-year median of 3.51. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 8.35. The Biotechnology industry median PB Ratio is 2.82. Jinyu Bio-Technology Co's value of 2.30 is 18.4% below this industry median. Based on the distribution chart, Jinyu Bio-Technology Co ranks #512 out of 1229 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jinyu Bio-Technology Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinyu Bio-Technology Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jinyu Bio-Technology Co ranks #512 out of 1229 companies for PB Ratio. This puts Jinyu Bio-Technology Co in the upper half of its industry. The industry median PB Ratio is 2.82. Jinyu Bio-Technology Co's value of 2.30 is 18.4% below this benchmark. Historically, Jinyu Bio-Technology Co's own PB Ratio has ranged from 1.20 to 8.35 over the past decade. While the company's 10-year median is 3.51 vs. the industry median of 2.82, Jinyu Bio-Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jinyu Bio-Technology Co's current PB Ratio of 2.30 is 18.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jinyu Bio-Technology Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinyu Bio-Technology Co's current PB Ratio is 2.30, which is 34% below median its own 10-year median of 3.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinyu Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co (SHSE:600201) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.34, compared to a current price of ¥11.30 — trading 35.5% above its estimated fair value. The current PB Ratio is 2.30, which is 34% below median its 10-year median of 3.51 and 18.4% below the Biotechnology industry median of 2.82. Jinyu Bio-Technology Co's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Jinyu Bio-Technology Co (SHSE:600201), the current PB Ratio is 2.30 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinyu Bio-Technology Co (SHSE:600201) Overvalued in 2026?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co stock appears to be overvalued.
The current stock price of ¥11.30 is trading 35.5% above its estimated GF Value™ of ¥8.34.
GuruFocus considers Jinyu Bio-Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:600201:
PB Ratio: 2.30 (34% below median its 10-year median of 3.51)
GF Value™: ¥8.34 vs. price of ¥11.30 (35.5% above fair value)
Industry Position: 18.4% below the Biotechnology median (#512 of 1229)
No single metric tells the full story. See the SHSE:600201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.
65GF Score
Get the complete analysis for SHSE:600201
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600201 has been successfully added to your 
